Rybrevant Plus Lacluze Delivers Statistically Significant and Clinic Ally Meaningful Improvement in Overall Survival Benefit for Asian Patients WithEGFR-Mutated Non-Small Cell Lung Cancer in the Phase 3 Mariposa Study
December 09, 2025
December 09, 2025
RARITAN, New Jersey, Dec. 9 (TNSjou) -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
RYBREVANT(R) (amivantamab-vmjw) plus LAZCLUZE(R) (lazertinib) delivers statistically significant and clinic ally meaningful improvement in overall survival benefit for Asian patients withEGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
First and only chemotherapy-free combination in the first-line setting to demonstra . . .
* * *
RYBREVANT(R) (amivantamab-vmjw) plus LAZCLUZE(R) (lazertinib) delivers statistically significant and clinic ally meaningful improvement in overall survival benefit for Asian patients withEGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
First and only chemotherapy-free combination in the first-line setting to demonstra . . .